About CStone Pharma
CStone Pharma is a company based in Shanghai (China) founded in 2016. CStone Pharma has raised $410 million across 3 funding rounds from investors including Pfizer, Taikang Insurance Group and CITIC Capital. The company has 135 employees as of December 31, 2024. CStone Pharma operates in a competitive market with competitors including Brii Biosciences, Affinivax, Neon Therapeutics, Osivax and SpyBiotech, among others.
- Headquarter Shanghai, China
- Employees 135 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Cstone Pharmaceuticals
-
Annual Revenue
$56.85 M (USD)-13.86as on Dec 31, 2024
-
Net Profit
-$12.73 M (USD)75.63as on Dec 31, 2024
-
EBITDA
-$6.36 M (USD)91.83as on Dec 31, 2024
-
Total Equity Funding
$410 M (USD)
in 3 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Sep 29, 2020
-
Investors
Pfizer
& 13 more
-
Employee Count
135
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CStone Pharma
CStone Pharma is a publicly listed company on the HKEX with ticker symbol 2616 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of CStone Pharma
Unlock access to complete
Funding Insights of CStone Pharma
CStone Pharma has successfully raised a total of $410M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CStone Pharma
CStone Pharma has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Taikang Insurance Group and CITIC Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Locked | Locked | Locked | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Locked | Locked | Locked | |
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Locked | Locked | Locked |
Investor details for CStone Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CStone Pharma
Investment portfolio details for CStone Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CStone Pharma
Detailed financials for CStone Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cstone Pharma Comparisons
Peer comparison for CStone Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CStone Pharma
CStone Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Affinivax, Neon Therapeutics, Osivax and SpyBiotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Tumor-specific neoantigens are identified for personalized cancer vaccine development.
|
|
| Locked | Locked | Locked |
Vaccines against mutating pathogens are developed using nanoparticle technology.
|
|
| Locked | Locked | Locked |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
Detailed competitors of CStone Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cstone Pharma
Complete news archive for CStone Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CStone Pharma
CStone Pharma was founded in 2016.
CStone Pharma is headquartered in Shanghai, China.
CStone Pharma is a funded company, having raised a total of $410M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CStone Pharma is 135.
Annual revenue of CStone Pharma is $56.85M as on Dec 31, 2024.
CStone Pharma, a Shanghai-Suzhou startup, is developing and licensing novel drugs with a focus on immuno-oncology along with drugs for cardiovascular diseases, hematology and autoimmune diseases (e.g - rheumatoid arthritis). It has a robust oncology pipeline with eight assets in clinical stages. It is working on various targets including IDHm1, PDL-1, FGFR4, RET, PD-1, etc. The lead molecule, TIBSOVO has got FDA approval.
CStone Pharma's top competitors include Brii Biosciences, Osivax and Affinivax.
Yes, CStone Pharma is publicly traded on HKEX under the ticker symbol 2616.
CStone Pharma has 14 investors. Key investors include Pfizer, Taikang Insurance Group, CITIC Capital, Arch Venture Partners, and GIC.
The ticker symbol of CStone Pharma is 2616 on HKEX.